Loerop James
SEC CIK 1781549 · EDGAR
BoughtSold
Most active insiders at ACRS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Leonard Braden Michael | 10% | — | $1.36M |
| 2 | Kolbeck Roland Wilhelm | CSO | — | — |
| 3 | Hall Jesse Wayne | Chief Medical Off | — | — |
| 4 | Davis Hugh M. | Pres, COO, Dir | — | — |
| 5 | Balthaser Kevin | CFO | — | — |
| 6 | Loerop James | Chief Business Off | — | — |
| 7 | Humphries William D. | Dir | — | — |
| 8 | Molineaux Christopher P. | Dir | — | — |
| 9 | Walker Neal | CEO, Dir | — | — |
| 10 | Mehra Anand | Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMA | 2026-02-05 | 2026-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +33.5K | 188.0K | +22% | — |
| DA | 2026-02-05 | 2026-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $3.51 | -10.7K | 177.3K | -6% | -$37.5K |
| D | 2026-02-05 | 2026-02-03 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +20.9K | 198.2K | +12% | — |
| D | 2026-02-05 | 2026-02-03 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $3.47 | -5,937 | 192.3K | -3% | -$20.6K |
| 2026-02-03 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $2.48 | -16.0K | 102.8K | -13% | -$39.6K | |
| A | 2026-02-03 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $2.48 | -16.0K | 102.8K | -13% | -$39.6K |
| DM | 2026-01-05 | 2025-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $2.99 | -40.2K | 143.1K | -22% | -$120.1K |
| DM | 2026-01-05 | 2025-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +91.9K | 161.2K | +133% | — |
| DM | 2025-02-04 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +33.5K | 96.5K | +53% | — |
| D | 2025-02-04 | 2025-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $2.48 | -15.4K | 103.3K | -13% | -$38.3K |
| DM | 2025-01-03 | 2024-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +91.9K | 93.8K | +4,767% | — |
| DM | 2025-01-03 | 2024-12-31+ | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $2.48 | -40.7K | 75.7K | -35% | -$100.8K |
| DM | 2024-02-05 | 2024-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +18.8K | 32.9K | +132% | — |
| DM | 2024-02-05 | 2024-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | F - Tax | $1.20 | -6,421 | 29.1K | -18% | -$7,705 |
| 2023-08-28 | 2023-08-28 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | P - Purchase | $6.80 | +14.7K | 21.7K | +211% | +$100.0K | |
| 2023-02-10 | 2023-02-08 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | S - Sale | $13.89 | -4,267 | 6,983 | -38% | -$59.3K | |
| D | 2023-02-03 | 2023-02-01 | ACRS | Aclaris Therapeutics, Inc. | Loerop James | Chief Business Off | M - OptEx | — | +11.2K | 11.2K | New | — |
| D | 2021-07-12 | 2021-07-08 | ANIK | Anika Therapeutics, Inc. | Loerop James | EVP Business Development | M - OptEx | $0.00 | +3,000 | 6,323 | +90% | $0 |
| D | 2021-07-12 | 2021-07-08 | ANIK | Anika Therapeutics, Inc. | Loerop James | EVP Business Development | F - Tax | $43.24 | -731 | 5,592 | -12% | -$31.6K |
Purchase Sale Sale after option exercise All abbreviations